'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Ajanta Pharma has increased 11.04% to Rs 1170.41 crore. Operating profit margin has declined from 26.40% to 25.39%, leading to 6.77% rise in operating profit to Rs 297.15 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 23.78% to 16.49%. Purchase of finished goods cost rose from 3.71% to 6.92%. Employee cost increased from 21.44% to 24.16%. Other expenses rose from 25.51% to 26.77%.
Other income fell 48.99% to Rs 18.11 crore. PBIDT rose 0.46% to Rs 315.26 crore. Provision for interest rose 296.73% to Rs 6.07 crore. Loan funds rose to Rs 31.17 crore as of 31 March 2025 from Rs 30.52 crore as of 31 March 2024. Inventories rose to Rs 739.29 crore as of 31 March 2025 fro...
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-May-2025)
Epigral
Capex in FY2025 was Rs 195 crore
-
(05-May-2025)
Voltamp Transformers
Growth in net restricted to 4% hit by lower OPM, lower OI and higher taxation
-
(05-May-2025)
Kotak Mahindra Bank
Better margins and asset quality, loan growth moderates
-
(04-May-2025)
State Bank of India
Profit declines on high provisions, asset quality remains healthy
|
|